Furthermore, the effects of GLI2 inhibition on glioma growth were supported by the lower protein levels of ARHGEF16 as well as Ki67 and MMP9 in GLI2A, GANT61 group than in GLI2A, vehicle group, as determined by immunohistochemistry (Fig. 6f). Here, MMP9 is linked to central nervous system cancer.